Acura Pharmaceuticals Inc (ACUR):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Acura Pharmaceuticals Inc (ACUR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10003
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Acura Pharmaceuticals Inc (Acura) is a specialty pharmaceutical company that researches, develops, and commercializes tamper-resistant products to prevent the abuse and misuse of medication. The company’s proprietary technologies, Aversion, Limitx and Impede, are used to prevent product tampering associated with opioid abuse. Its Impede technology helps minimize the extraction and conversion of pseudoephedrine into methamphetamine. Limitx reduces the level of opioid release when several tablets are swallowed. Aversion irritates the nasal passages upon snorting the product. Its product portfolio includes Oxaydo, an opioid analgesic; Nexafed and Nexafed Sinus Pressure plus that contain pseudoephedrine. The company markets its products in the US and Canada. Acura is headquartered in Palatine, Illinois, the US.

Acura Pharmaceuticals Inc (ACUR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Acura Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Licensing Agreements 12
MainPointe Pharma Enters into Licensing Agreement with Acura Pharma 12
KemPharm Enters into Licensing Agreement with Acura Pharma 14
Egalet Enters into Licensing Agreement with Acura Pharma 15
Equity Offering 16
Acura Pharma Raises USD4 Million in Private Placement of Units 16
Acura Pharmaceuticals Files Registration Statement for Public Offering of Shares 17
Acura Pharma Raises USD7.6 Million in Private Placement of Shares 18
Acura Pharma Completes Second Tranche Of Public Offering Of Shares For US$3.4 Million 20
Acquisition 21
Acura Pharma Plans to Sell Itself 21
Acura Pharmaceuticals Inc – Key Competitors 22
Acura Pharmaceuticals Inc – Key Employees 23
Acura Pharmaceuticals Inc – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Financial Announcements 25
Aug 14, 2018: Acura Pharmaceuticals announces second quarter 2018 financial results 25
Jun 29, 2018: Acura Pharmaceuticals Reports First Quarter 2018 Financial Results 26
Jun 07, 2018: Acura Pharmaceuticals Announces Fourth Quarter 2017 and Full Year 2017 Financial Results 27
Nov 13, 2017: Acura Pharmaceuticals Announces Third Quarter 2017 Financial Results 28
Aug 14, 2017: Acura Pharmaceuticals Announces Second Quarter 2017 Financial Results 29
May 12, 2017: Acura Pharmaceuticals Announces First Quarter 2017 Financial Results 30
Mar 31, 2017: Acura Pharmaceuticals Announces Fourth Quarter 2016 and Full Year 2016 Financial Results 31
Product News 32
09/11/2017: Acura Pharmaceuticals Presenting New LIMITx Clinical Data at the 19th Annual Rodman & Renshaw Conference 32
06/28/2017: Acura Pharmaceuticals Advances LTX-04 and its LIMITx Technology 33
Clinical Trials 34
May 18, 2017: Acura Pharmaceutical Initiates Second Clinical Study on LTX-04 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Acura Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Acura Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
MainPointe Pharma Enters into Licensing Agreement with Acura Pharma 12
KemPharm Enters into Licensing Agreement with Acura Pharma 14
Egalet Enters into Licensing Agreement with Acura Pharma 15
Acura Pharma Raises USD4 Million in Private Placement of Units 16
Acura Pharmaceuticals Files Registration Statement for Public Offering of Shares 17
Acura Pharma Raises USD7.6 Million in Private Placement of Shares 18
Acura Pharma Completes Second Tranche Of Public Offering Of Shares For US$3.4 Million 20
Acura Pharma Plans to Sell Itself 21
Acura Pharmaceuticals Inc, Key Competitors 22
Acura Pharmaceuticals Inc, Key Employees 23
Acura Pharmaceuticals Inc, Subsidiaries 24

List of Figures
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Acura Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Acura Pharmaceuticals Inc (ACUR):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • SNC-Lavalin Group Inc (SNC)-石油・ガス分野:企業M&A・提携分析
    Summary SNC-Lavalin Group Inc. (SNC) is global provider of engineering and construction services. It offers a range of engineering, procurement, construction, project management services to various industries, including oil and gas, mining and metallurgy, infrastructure and power. In addition, the c …
  • APR Applied Pharma Research SA-製薬・医療分野:企業M&A・提携分析
    Summary APR Applied Pharma Research SA (APR) is a healthcare company which focuses on the development and licenses of healthcare products for rare therapeutic areas. The company offers consumer health products, prescription healthcare products and therapeutic products. APR’s product pipeline portfol …
  • Quantum Fuel Systems LLC:企業の戦略的SWOT分析
    Quantum Fuel Systems LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Abraxas Petroleum Corp Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Abraxas Petroleum Corp Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Abraxas Petroleum Corp (Abraxas) is an oil and gas company. The company offers exploration, production and development of oil and gas properties across the US. Its properties are located in Mi …
  • Lotus Pharmaceutical Co Ltd (1795):企業の財務・戦略的SWOT分析
    Summary Lotus Pharmaceutical Co Ltd (Lotus Pharmaceutical), a subsidiary of Alvogen Inc is a pharmaceutical company that develops and sells pharmaceutical products. The company provides products that are used in the treatment of rheumatology, cancer, cardiology, dyslipidemia, hypertension, woman hea …
  • Boustead Heavy Industries Corp Bhd:企業の戦略・SWOT・財務情報
    Boustead Heavy Industries Corp Bhd - Strategy, SWOT and Corporate Finance Report Summary Boustead Heavy Industries Corp Bhd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Zoll Medical Corporation-医療機器分野:企業M&A・提携分析
    Summary ZOLL Medical Corporation (Zoll), a subsidiary of Asahi Kasei Corporation, is a provider of medical devices and software solutions for advance emergency care. The company designs, manufactures and markets resuscitation devices and systems used for resuscitation and acute critical care victims …
  • Noerr LLP:企業の戦略的SWOT分析
    Noerr LLP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Valener Inc (VNR):石油・ガス:M&Aディール及び事業提携情報
    Summary Valener Inc (Valener) is an investment holding company that focuses on the energy sector. Through its investments in energy portfolio, the company offers storage, distribution, transportation and allied energy services. The company has interest in Gaz Metro and is its limited partner. Gaz Me …
  • Intercontinental Hotels Group Plc:企業の戦略・SWOT・財務分析
    Intercontinental Hotels Group Plc - Strategy, SWOT and Corporate Finance Report Summary Intercontinental Hotels Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Parkway Pantai Ltd:企業の戦略的SWOT分析
    Parkway Pantai Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Elite Pharmaceuticals Inc (ELTP):製薬・医療:M&Aディール及び事業提携情報
    Summary Elite Pharmaceuticals Inc (Elite) is a specialty pharmaceutical company focuses on the development of oral sustained and controlled release drug products. The company manufactures and develops generic drugs with Abbreviated New Drug Applications (ANDA) and branded drugs with New Drug Applica …
  • Companhia Riograndense de Mineracao:企業の戦略・SWOT・財務分析
    Companhia Riograndense de Mineracao - Strategy, SWOT and Corporate Finance Report Summary Companhia Riograndense de Mineracao - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Arab International Bank:企業の戦略・SWOT・財務情報
    Arab International Bank - Strategy, SWOT and Corporate Finance Report Summary Arab International Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • BelAZ:企業の戦略・SWOT・財務分析
    BelAZ - Strategy, SWOT and Corporate Finance Report Summary BelAZ - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, provid …
  • Epinex Diagnostics Inc:医療機器:M&Aディール及び事業提携情報
    Summary Epinex Diagnostics Inc (Epinex Diagnostics) is a medical device company that develops rapid diagnostic tests. The company’s products include over-the-counter test device, Epinex G1A Test system, Epinex ACR Test system, Epinex SimplySure PT-INR Test system and point-of-care test device, among …
  • Sudarshan Chemical Industries Ltd (SUDARSCHEM):企業の財務・戦略的SWOT分析
    Sudarshan Chemical Industries Ltd (SUDARSCHEM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key str …
  • Power Machines:企業の戦略的SWOT分析
    Power Machines - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • TMX Group Limited (X):企業の財務・戦略的SWOT分析
    TMX Group Limited (X) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • IRPC Public Company Limited:企業の戦略・SWOT・財務分析
    IRPC Public Company Limited - Strategy, SWOT and Corporate Finance Report Summary IRPC Public Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆